



---

# **Exela Technologies, Inc. Reports Second Quarter 2018 Results; Revenue of \$410.4 million an increase of 17.3% over Q2 2017 on a pro forma basis; Net Loss of \$25.2 million; EBITDA of \$51.3 million, an increase of 23.8% over Q2 2017 on a pro forma basis; Rea**

Aug 09, 2018

Second Quarter 2018 Highlights:

Revenue of \$410.4 million, representing 17.3% growth over Q2 2017 on a pro forma basis  
Net loss of \$25.2 million, a year-over-year improvement from a pro forma net loss of \$27.9 million

EBITDA of \$51.3 million, representing 23.8% growth over Q2 2017 on a pro forma basis

Adjusted EBITDA of \$70.1 million, representing 9.0% growth over Q2 2017 on a pro forma basis

Achieved \$15.8 million of savings during the second quarter of 2018 and reiterates total anticipated savings of \$40 million to \$45 million during 2018

Operating income of \$11.9 million, representing 19.3% growth over Q2 2017 on a pro forma basis

Previously announced share buyback program remains in effect and total shares of common stock purchased to-date totaled 1,043,497

Reaffirms 2018 and long-term guidance

**Irving, Texas, Aug 09, 2018 (GLOBE NEWSWIRE)** -- Exela Technologies, Inc. ("Exela" or the "Company") (NASDAQ:XELA), one of the largest global providers of platforms for Business Process Automation ("BPA"), announced today its financial results for the second quarter ended June 30, 2018.

"I am pleased to report second quarter revenue grew 17.3% and EBITDA grew 23.8% on a pro forma basis. We saw growth across customers and geographies, and increasing demand for our services. With approximately 200 customers generating annual revenue over \$1 million, backed by strong quarterly results and a large contracted backlog, we are reaffirming our outlook for the full-year 2018," said Ronald Cogburn, Chief Executive Officer of Exela.



---

Financial information contained in this press release, unless otherwise stated, is presented pro forma for the business combination of Quinpario Acquisition Corp. 2, SourceHOV Holdings, Inc. (“SourceHOV”) and Novitex Holdings, Inc. (“Novitex”), which closed on July 12, 2017 (the “Business Combination”). The primary pro forma adjustment is to include the results of Novitex for the period January 1, 2017 to June 30, 2017. For more information, please refer to the reconciliation of reported to pro forma financial results contained in the Schedules to this press release.

## **Second Quarter Ended June 30, 2018 Financial Highlights**

(Note: all Q2 2017 numbers, unless otherwise stated, are presented on a pro forma basis.)

- **Revenue:** Revenue of \$410.4 million, an increase of 17.3% from \$350.0 million in the second quarter of 2017, and an increase of 4.4% from \$393.2 million in the first quarter of 2018. Please refer to the pro forma revenue reconciliation contained in this press release for the second quarter of 2017. Information and Transaction Processing Solutions (“ITPS”) revenue was \$330.1 million, an increase of 22.1% year-over-year, driven primarily by increased volumes and expansion of services within new and existing customers. The acquisition of Asterion International in April 2018 added 7.7% of the growth in ITPS revenue. Healthcare Solutions (“HS”) revenue declined 3.0% to \$56.3 million due to lower volumes received from a single customer due to that customer’s loss of a contract; expect to see year-over-year revenue growth within Healthcare Solutions. Legal and Loss Prevention Services (“LLPS”) revenue was \$23.9 million, an increase of 10.9%. Results in LLPS are event driven and in-line with expectations. The sale of a small non-core subsidiary during the quarter reduced LLPS growth by 2.5%.
- An increase from 6 to 8 customers generating over \$25 million in annual revenue.
- Broad revenue base with top 150 customers comprising 66% of revenue.
- Added 8 contracts generating over \$1 million Annual Contract Value (“ACV”).
- **Net Loss:** Net Loss for the second quarter of 2018 totaled \$25.2 million, an improvement of \$2.7 million when compared to a pro forma net loss of \$27.9 million in the second quarter of 2017. The improvement in second quarter 2018 net loss was driven by \$6.2 million higher operating income along with higher sundry and other income and lower interest expense offset by higher income tax expense of \$3.5 million.
- **Adjusted EBITDA:** Adjusted EBITDA was \$70.1 million, an increase of 9.0% when compared to pro forma Adjusted EBITDA of \$64.3 million in the second quarter of 2017. The increase in second quarter 2018 Adjusted EBITDA was primarily driven by revenue growth and the impact of the Company’s cost savings initiatives, partially offset by investments in the Company’s revenue growth initiatives, and higher public company costs.
- **Adjusted EBITDA Margin:** Adjusted EBITDA margin was 17.1%, representing a decline of 130 basis points when compared to an Adjusted EBITDA margin of 18.4% in the second quarter of 2017. The decline in Adjusted EBITDA margin was primarily driven by investments in the Company’s revenue growth initiatives, and higher public company costs, offset by revenue growth and the impact of the Company’s cost savings



initiatives.

- **Capital Expenditures:** Capital Expenditures were 1.9% of Q2 2018 revenue compared to 3.5% in Q2 2017.
- **Common Stock:** As of June 30, 2018, total shares outstanding were 158,151,562 which includes 5,586,344 shares for outstanding preferred shares on an as converted basis.
- **Share buyback:** During Q2 2018, the Company purchased 768,693 number of shares. The cumulative shares repurchased under the Company's share buyback program totaled 1,043,497 in the aggregate since the inception of the program.

## Balance Sheet and Liquidity

At June 30, 2018, Exela's total liquidity was \$139.7 million, measured as \$60.3(1) million of cash excluding restricted cash, and an undrawn revolving credit facility of \$100 million with \$20.6 million reserved for letters of credit. Total net debt was \$1.343 billion.

(1) – Cash, restricted cash and cash equivalents total of \$86.9 million less \$26.6 million of restricted cash that is subject to legal restrictions as of June 30, 2018.

## Reaffirms 2018 and long-term guidance 2018 guidance

- Revenue range \$1.55 billion to \$1.58 billion, year-over-year growth of 6.5% to 8.5% on a pro forma basis.
- Adjusted EBITDA range \$295 million to \$310 million, year-over-year growth of 20% to 26% on a pro forma basis.
- Further Adjusted EBITDA in the range of \$330 million to \$355 million.
- Guidance includes delivering \$40 million to \$45 million in savings during 2018 with remainder to be achieved beyond 2018.

## Long-term guidance

- Revenue growth in the range of 3% to 4%
- Adjusted EBITDA margin guidance in the range of 22% to 23%
- Free Cash Flow Margin of 19% to 20%

Guidance is based on constant-currency.

**Note on Outlook:** The company has not forecasted net income/(loss) on a forward-looking



---

basis due to the high variability and difficulty in predicting certain items that affect GAAP net income/(loss). Adjusted EBITDA should not be used to predict net income/(loss) as the difference between the two measures is variable.

Further Adjusted EBITDA gives effect to historical acquisitions and other cost saving initiatives as if they had been included in the financial information from the beginning of each period presented.

Free Cash Flow Margin is defined as Adjusted EBITDA, less capex (assumed at 3% of revenue), divided by revenue.

The above guidance is based on second quarter 2018 results.

Please refer to attached schedules for reconciliations. Numbers may not total due to rounding.

### **Earnings Conference Call and Audio Webcast**

Exela will host a conference call to discuss its second quarter 2018 financial results today at 5:00 p.m. EDT. To access this call, dial 800-860-2442 or +412-858-4600 (international). A replay of this conference call will be available through August 16, 2018 at 877-344-7529 or +412-317-0088 (international). The replay passcode is 10121267. A live webcast of this conference call will be available on the "Investors" page of the Company's website ([www.exelatech.com](http://www.exelatech.com)). A supplemental slide presentation that accompanies this call and webcast can be found on the investor relations website (<https://investors.exelatech.com>) and will remain available after the call. Exela has also posted additional historical financial information regarding SourceHOV and on a combined basis to its investor relations website, (<https://investors.exelatech.com>).

### **About Exela:**

Exela Technologies, Inc. ("Exela") is a global business process automation ("BPA") leader combining industry-specific and industry-agnostic enterprise software and solutions with decades of experience. Our BPA suite of solutions are deployed in banking, healthcare, insurance and other industries to support mission critical environments. Exela is a leader in work flow automation, attended and un-attended cognitive automation, digital mail rooms, print communications, and payment processing with deployments across the globe.

Exela partners with customers to improve user experience and quality through operational efficiency. Exela serves over 3,700 customers across more than 50 countries, through a secure, cloud-enabled global delivery model. We are 22,000 employees strong across the Americas, Europe and Asia. Our customer list includes 60% of the Fortune® 100, along with many of the world's largest retail chains, banks, law firms, healthcare insurance payers and providers and telecom companies. Find out more at [www.exelatech.com](http://www.exelatech.com)



---

Follow Exela on Twitter: <https://twitter.com/exelatech>

Follow Exela on LinkedIn: <https://www.linkedin.com/company/11174620/>

## **About Non-GAAP Financial Measures**

This press release includes EBITDA, Adjusted EBITDA, Further Adjusted EBITDA, and Free Cash Flow Margin, each of which is a financial measure that is not prepared in accordance with U.S. generally accepted accounting principles (“GAAP”). Exela believes that the presentation of these non-GAAP financial measures will provide useful information to investors in assessing our financial performance, results of operations and liquidity and allows investors to better understand the trends in our business and to better understand and compare our results. Exela’s board of directors and management use EBITDA, Adjusted EBITDA, Further Adjusted EBITDA, and Free Cash Flow Margin to assess Exela’s financial performance, because it allows them to compare Exela’s operating performance on a consistent basis across periods by removing the effects of Exela’s capital structure (such as varying levels of debt and interest expense, as well as transaction costs resulting from the Business Combination and other such capital markets based activities. Adjusted EBITDA and Further Adjusted EBITDA also seek to remove the effects of integration and related costs to achieve the savings, any expected reduction in operating expenses due to the Business Combination, asset base (such as depreciation and amortization) and other similar non-routine items outside the control of our management team. Backlog is a measure of the estimated total dollar value of services expected to be delivered by Exela to its customers under existing contractual terms. Backlog is considered a non-GAAP financial measure as defined by SEC Regulation G. Estimates of future financial results are inherently unreliable. Our methodology for determining backlog may not be comparable to the methodologies used by others. Exela does not consider these non-GAAP measures in isolation or as an alternative to liquidity or financial measures determined in accordance with GAAP. A limitation of these non-GAAP financial measures is that they exclude significant expenses and income that are required by GAAP to be recorded in Exela’s financial statements. In addition, they are subject to inherent limitations as they reflect the exercise of judgments by management about which expenses and income are excluded or included in determining these non-GAAP financial measures and therefore the basis of presentation for these measures may not be comparable to similarly-titled measures used by other companies. These non-GAAP financial measures are not required to be uniformly applied, are not audited and should not be considered in isolation or as substitutes for results prepared in accordance with GAAP. Net loss is the GAAP measure most directly comparable to the non-GAAP measures presented here. For reconciliation of the comparable GAAP measures to these non-GAAP financial measures, see the schedules to this release. Optimization and restructuring expenses and merger



adjustments are primarily related to the implementation of strategic actions and initiatives related to the Business Combination. All of these costs are variable and dependent upon the nature of the actions being implemented and can vary significantly driven by business needs. Accordingly, due to that significant variability, we exclude these charges since we do not believe they truly reflect our past, current or future operating performance.

## **Forward-Looking Statements**

Certain statements included in this press release are not historical facts but are forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Forward-looking statements generally are accompanied by words such as “may”, “should”, “would”, “plan”, “intend”, “anticipate”, “believe”, “estimate”, “predict”, “potential”, “seem”, “seek”, “continue”, “future”, “will”, “expect”, “outlook” or other similar words, phrases or expressions. These forward-looking statements include statements regarding our industry, future events, the estimated or anticipated future results and benefits of the business combination of Quinpario Acquisition Corp. 2, SourceHOV Holdings, Inc., (“SourceHOV”) and Novitex Holdings, Inc. (“Novitex”), which formed Exela Technologies, Inc. (“Exela”), and closed on July 12, 2017 (including the related transactions, the “Business Combination”), future opportunities for the combined company, and other statements that are not historical facts such as our estimated backlog. These statements are based on the current expectations of Exela management and are not predictions of actual performance. These statements are subject to a number of risks and uncertainties regarding Exela’s business, and actual results may differ materially. These risks and uncertainties include, but are not limited to, changes in the business environment in which Exela operates and general financial, economic, regulatory and political conditions affecting the industries in which Exela operates; changes in taxes, governmental laws and regulations; competitive product and pricing activity; failure to realize the anticipated benefits of the Business Combination, including as a result of a delay or difficulty in integrating the businesses of SourceHOV and Novitex or the inability to realize the expected amount and timing of cost savings and operating synergies of the Business Combination; and those factors discussed under the heading “Risk Factors” in Exela’s Annual Report on Form-10-K filed with the Securities and Exchange Commission (“SEC”) on March 16, 2018. In addition, forward-looking statements provide Exela’s expectations, plans or forecasts of future events and views as of the date of this communication. Exela anticipates that subsequent events and developments will cause Exela’s assessments to change. These forward-looking statements should not be relied upon as representing Exela’s assessments as of any date subsequent to the date of this press release.

## **Exela Technologies**

### **Condensed Consolidated Balance Sheets as of June 30, 2018 and December 31, 2017**

*(in thousands of United States dollars unless otherwise noted)*



---

|  | <b>June 30,<br/>2018</b> | <b>December 31,<br/>2017</b> |
|--|--------------------------|------------------------------|
|  | (Unaudited)              |                              |
| <b>Assets</b>  |                          |                              |
| Current assets   |                          |                              |
| Cash and cash equivalents  | \$ 55,783                | \$ 39,000                    |
| Restricted cash  | 31,088                   | 42,489                       |
| Accounts receivable, net of allowance for doubtful accounts of \$4,488 and \$3,725, respectively | 26,2260                  | 229,704                      |
| Inventories, net   | 15,088                   | 11,922                       |
| Prepaid expenses and other current assets  | 24,108                   | 24,596                       |
| Total current assets   | <b>388,326</b>           | <b>347,711</b>               |
| Property, plant and equipment, net   | 135,585                  | 132,908                      |
| Goodwill   | 748,708                  | 747,325                      |
| Intangible assets, net   | 419,725                  | 464,984                      |
| Deferred income tax assets   | 15,280                   | 9,019                        |
| Other noncurrent assets  | 21,276                   | 12,891                       |
| Total assets   | <b>\$ 1,728,901</b>      | <b>\$ 1,714,838</b>          |
| <b>Liabilities and Stockholders' Deficit</b>   |                          |                              |
| <b>Liabilities</b>   |                          |                              |
| Current liabilities  |                          |                              |
| Accounts payable   | \$ 86,304                | \$ 81,263                    |
| Related party payables   | 11,987                   | 14,445                       |
| Income tax payable   | 5,385                    | 3,612                        |
| Accrued liabilities  | 40,737                   | 49,383                       |
| Accrued compensation and benefits  | 50,905                   | 46,925                       |
| Accrued interest   | 48,885                   | 55,102                       |
| Customer deposits  | 36,997                   | 31,656                       |
| Deferred revenue   | 20,654                   | 12,709                       |
| Obligation for claim payment   | 94,233                   | 42,489                       |
| Current portion of capital lease obligations   | 16,568                   | 15,611                       |
| Current portion of long-term debt  | 16,299                   | 20,565                       |
| <b>Total current liabilities</b>   | <b>428,954</b>           | <b>373,760</b>               |
| Long-term debt, net of current maturities  | 1,281,697                | 1,276,094                    |
| Capital lease obligations, net of current maturities   | 25,193                   | 25,958                       |
| Pension liability  | 30,471                   | 25,496                       |

---





|   |                     |                     |
|---|---------------------|---------------------|
| Deferred income tax liabilities   | 5,016               | 5,362               |
| Long-term income tax liability  | 3,470               | 3,470               |
| Other long-term liabilities   | 16,208              | 14,704              |
| <b>Total liabilities</b>  | <b>\$ 1,791,009</b> | <b>\$ 1,724,844</b> |
| Commitments and Contingencies (Note 9)  |                     |                     |
| <b>Stockholders' deficit</b>  |                     |                     |
| Common stock, par value of \$0.0001 per share;<br>1,600,000,000 shares<br>authorized; 152,565,218 shares issued and 151,747,225<br>outstanding at<br>June 30, 2018 and 150,578,451 shares issued and<br>150,529,151<br>outstanding at December 31, 2017 | \$ 15               | \$ 15               |
| Preferred stock, par value of \$0.0001 per share;<br>20,000,000 shares<br>authorized; 4,569,233 shares issued and outstanding at<br>June 30, 2018 and<br>6,194,233 shares issued and outstanding at December<br>31, 2017                                | 1                   | 1                   |
| Additional paid in capital  | 482,018             | 482,018             |
| Less:common stock held in treasury, at cost; 817,993<br>shares at June 30,<br>2018 and 49,300 shares at December 31, 2017   | (3,728)             | (249)               |
| Equity based compensation   | 36,980              | 34,085              |
| Accumulated deficit   | (565,222)           | (514,628)           |
| <b>Accumulated other comprehensive loss:</b>  |                     |                     |
| Foreign currency translation adjustment   | (1,341)             | (194)               |
| Unrealized pension actuarial losses, net of tax   | (10,831)            | (11,054)            |
| Total accumulated other comprehensive loss  | (12,172)            | (11,248)            |
| <b>Total stockholders' deficit</b>  | <b>(62,108)</b>     | <b>(10,006)</b>     |
| <b>Total liabilities and stockholders' deficit</b>  | <b>\$ 1,728,901</b> | <b>\$ 1,714,838</b> |

## **Exela Technologies**

### **Condensed Consolidated Statements of Operations for the Three and Six Months ended June 30, 2018 and 2017 (Loss) (Unaudited)**

*(in thousands of United States dollars except share and per share amounts unless otherwise noted)*





|  | <b>Three Months ended June 30,</b> |                    | <b>Six Months ended June 30,</b> |                    |
|--|------------------------------------|--------------------|----------------------------------|--------------------|
|  | <b>2018</b>                        | <b>2017</b>        | <b>2018</b>                      | <b>2017</b>        |
| Revenue  | \$ 410,382                         | \$ 209,382         | \$ 803,549                       | \$ 427,642         |
| Cost of revenue (exclusive of depreciation and amortization) | 313,954                            | 140,418            | 607,746                          | 284,126            |
| Selling, general and administrative expenses                 | 46,723                             | 34,998             | 92,318                           | 70,578             |
| Depreciation and amortization                                | 36,368                             | 21,406             | 74,386                           | 42,727             |
| Related party expense  | 1,402                              | 2,456              | 2,508                            | 4,841              |
| <b>Operating income</b>                                      | <b>11,935</b>                      | <b>10,104</b>      | <b>26,591</b>                    | <b>25,370</b>      |
| <b>Other expense (income), net:</b>                          |                                    |                    |                                  |                    |
| Interest expense, net  | 38,527                             | 27,869             | 76,544                           | 54,088             |
| Sundry expense (income), net                                 | (2,325)                            | (327)              | (2,389)                          | 2,397              |
| Other income, net  | (704)                              | -                  | (4,032)                          | -                  |
| <b>Net loss before income taxes</b>                          | <b>(23,563)</b>                    | <b>(17,438)</b>    | <b>(43,532)</b>                  | <b>(31,115)</b>    |
| Income tax expense   | (1,619)                            | (2,074)            | (5,644)                          | (4,078)            |
| <b>Net loss</b>  | <b>(25,182)</b>                    | <b>(19,512)</b>    | <b>(49,176)</b>                  | <b>(35,193)</b>    |
| Cumulative dividends for Series A Preferred Stock            | (914)                              | -                  | (1,828)                          | -                  |
| <b>Net loss attributable to common stockholders</b>          | <b>\$ (26,096)</b>                 | <b>\$ (19,512)</b> | <b>\$ (51,004)</b>               | <b>\$ (35,193)</b> |
| Net loss per share - basic and diluted                       | (0.17)                             | (0.28)             | (0.34)                           | (0.50)             |

## **Exela Technologies**

### **Condensed Consolidated Statements of Cash Flows for the Six Months ended June 30, 2018 and 2017 (Unaudited)**

*(in thousands of United States dollars unless otherwise noted)*

|   | <b>Six Months ended June 30,</b> |             |
|---|----------------------------------|-------------|
|   | <b>2018</b>                      | <b>2017</b> |
| <b>Cash flows from operating activities</b> |                                  |             |
| Net loss                                    | \$ (49,176)                      | \$ (35,193) |
| Adjustments to reconcile net loss           |                                  |             |



---

|   |                 |                |
|---|-----------------|----------------|
| Depreciation and amortization   | 74,386          | 42,727         |
| Debt discount and debt issuance cost amortization                           | 5,272           | 7,027          |
| Provision for doubtful accounts   | 1,857           | 192            |
| Deferred income tax benefit   | 705             | 617            |
| Share-based compensation expense  | 2,895           | 2,217          |
| Foreign currency remeasurement  | (1,156)         | 972            |
| Loss on sale of assets  | 1,340           | 26             |
| Fair value adjustment for interest rate swap                                | (4,675)         | -              |
| Change in operating assets and liabilities, net of effect from acquisitions |                 |                |
| Accounts receivable   | (19,813)        | (49)           |
| Prepaid expenses and other assets   | (1,603)         | (1,794)        |
| Accounts payable and accrued liabilities                                    | 40,677          | 24,543         |
| Related party payables  | (2,458)         | (8,025)        |
| <b>Net cash provided by operating activities</b>                            | <b>48,251</b>   | <b>33,260</b>  |
| <b>Cash flows from investing activities</b>                                 |                 |                |
| Purchases of property, plant and equipment                                  | (10,244)        | (3,409)        |
| Additions to internally developed software                                  | (2,115)         | (4,731)        |
| Costs to obtain and fulfill a contract                                      | (3,695)         | (6,038)        |
| Cash paid in acquisition net of cash - Asterion                             | (4,145)         | -              |
| Proceeds on sale of assets  | (1,014)         | 4,392          |
| <b>Net cash used in investing activities</b>                                | <b>(19,185)</b> | <b>(9,786)</b> |
| <b>Cash flows from financing activities</b>                                 |                 |                |
| Change in bank overdraft  | -               | (210)          |
| Common share repurchases  | (3,479)         |                |
| Proceeds from financing obligations   | 2,152           | 3,008          |
| Contribution from shareholders  | -               | 20,546         |
| Cash paid for equity issue costs  | (7,500)         | -              |
| Borrowings from revolver and swing-line loan                                | 30,000          | 72,600         |
| Repayments from revolver and swing line loan                                | (30,000)        | (72,500)       |
| Principal payments on long-term obligations                                 | (14,447)        | (28,153)       |
| <b>Net cash used in financing activities</b>                                | <b>(23,274)</b> | <b>(4,709)</b> |
| Effect of exchange rates on cash  | (410)           | 240            |
| <b>Net increase in cash and cash equivalents</b>                            | <b>5,382</b>    | <b>19,005</b>  |
| Cash, restricted cash, and cash equivalents                                 |                 |                |

---



---

|                     |           |           |
|---------------------|-----------|-----------|
| Beginning of period | 81,489    | 34,253    |
| End of period       | \$ 86,871 | \$ 53,258 |

**Supplemental cash flow data:**

|  |          |          |
|--|----------|----------|
| Income tax payments, net of refunds received | \$ 3,864 | \$ 2,032 |
| Interest paid                                | 76,353   | 32,566   |

**Noncash investing and financing activities:**

|  |       |       |
|--|-------|-------|
| Assets acquired through capital lease arrangements | 7,787 | 187   |
| Leasehold improvements funded by lessor            | 1,540 | -     |
| Accrued capital expenditures                       | 1,144 | 1,026 |

**Exela Technologies**

**Schedule 1: Pro Forma Second Quarter 2017 vs. Second Quarter 2018 Financial Performance**

| (\$ in millions)   | Q2 2018       | Pro forma Q2 2017 | % Change     |
|--|---------------|-------------------|--------------|
| <b>Revenue</b>   |               |                   |              |
| Information and Transaction Processing Solutions                       | \$330.1       | \$270.3           | 22.1%        |
| Healthcare Solutions   | 56.3          | 58.1              | -3.0%        |
| Legal and Loss Prevention Services                                     | 23.9          | 21.6              | 10.9%        |
| <b>Total Revenue</b>   | <b>410.4</b>  | <b>350.0</b>      | <b>17.3%</b> |
| Cost of revenue (exclusive of depreciation and amortization)           | 314.0         | 257.0             | 22.1         |
| Selling, general and administrative expenses (Including related party) | 48.1          | 51.8              | -7.1         |
| Depreciation and amortization  | 36.4          | 31.1              | 16.8         |
| <b>Operating income (loss)</b>   | <b>11.9</b>   | <b>10.0</b>       |              |
| Interest expense, net  | 38.5          | 40.0              |              |
| Sundry expense (income) & Other income, net                            | (3.0)         | (0.3)             |              |
| <b>Net loss before income taxes</b>                                    | <b>(23.6)</b> | <b>(29.7)</b>     |              |
| Income tax expense / (benefit)   | 1.6           | (1.9)             |              |
| <b>Net loss</b>  | <b>(25.2)</b> | <b>(27.9)</b>     |              |
| Depreciation and amortization  | 36.4          | 31.1              |              |

---



|   |               |               |             |
|---|---------------|---------------|-------------|
| Interest expense, net                   | 38.5          | 40.0          |             |
| Income tax expense / (benefit)          | 1.6           | (1.9)         |             |
| <b>EBITDA</b>                           | <b>51.3</b>   | <b>41.5</b>   |             |
| Transaction related costs               | 0.8           | 7.3           |             |
| Optimization and restructuring expenses | 13.0          | 10.2          |             |
| Non-cash charges / (gains)              | 4.9           | 5.4           |             |
| <b>Adjusted EBITDA</b>                  | <b>\$70.1</b> | <b>\$64.3</b> | <b>9.0%</b> |
| Adjusted EBITDA Margin                  | 17.1%         | 18.4%         |             |

## Exela Technologies

### Schedule 2: Pro Forma YTD 2017 vs. YTD 2018 Financial Performance

| (\$ in millions)   | YTD 2018      | Pro forma<br>YTD 2017 | % Change     |
|--|---------------|-----------------------|--------------|
| <b>Revenue</b>   |               |                       |              |
| Information and Transaction Processing Solutions                       | \$642.1       | \$549.7               | 16.8%        |
| Healthcare Solutions   | 114.9         | 117.1                 | -1.9%        |
| Legal and Loss Prevention Services                                     | 46.5          | 45.0                  | 3.5%         |
| <b>Total Revenue</b>   | <b>803.5</b>  | <b>711.8</b>          | <b>12.9%</b> |
| Cost of revenue (exclusive of depreciation and amortization)           | 607.7         | 518.9                 | 17.1%        |
| Selling, general and administrative expenses (Including related party) | 94.8          | 106.1                 | 10.6%        |
| Depreciation and amortization  | 74.4          | 62.2                  | 19.7%        |
| <b>Operating income (loss)</b>   | <b>26.6</b>   | <b>24.7</b>           |              |
| Interest expense, net  | 76.5          | 78.4                  |              |
| Sundry expense (income) & Other income, net                            | (6.4)         | 2.4                   |              |
| <b>Net loss before income taxes</b>                                    | <b>(43.5)</b> | <b>(56.1)</b>         |              |
| Income tax expense / (benefit)   | 5.6           | (2.9)                 |              |
| <b>Net loss</b>  | <b>(49.2)</b> | <b>(53.2)</b>         |              |
| Depreciation and amortization  | 74.4          | 62.2                  |              |
| Interest expense, net  | 76.5          | 78.4                  |              |
| Income tax expense / (benefit)   | 5.6           | (2.9)                 |              |
| <b>EBITDA</b>  | <b>107.4</b>  | <b>84.4</b>           |              |



|   |                |                |            |
|---|----------------|----------------|------------|
| Transaction related costs               | 1.9            | 17.3           |            |
| Optimization and restructuring expenses | 27.5           | 16.0           |            |
| Non-cash charges / (gains)              | 2.9            | 9.3            |            |
| <b>Adjusted EBITDA</b>                  | <b>\$139.7</b> | <b>\$127.0</b> | <b>10%</b> |
| Adjusted EBITDA Margin                  | 17.4%          | 17.8%          |            |

**Exela Technologies**  
**Schedule 3: Adjusted EBITDA Reconciliation - Pro Forma Second Quarter 2017**

| (\$ in millions)                        | Q2 2017 <sup>(1)</sup> |                |                 |
|---|------------------------|----------------|-----------------|
|   | As Reported            | Novitex        | Pro Forma       |
| <b>Net loss</b>                         | <b>(\$19.5)</b>        | <b>(\$8.4)</b> | <b>(\$27.9)</b> |
| Taxes                                   | 2.1                    | (3.9)          | (1.9)           |
| Interest expense                        | 27.9                   | 12.2           | 40.0            |
| Depreciation and amortization           | 21.4                   | 9.7            | 31.1            |
| <b>EBITDA</b>                           | <b>\$31.8</b>          | <b>\$9.6</b>   | <b>\$41.5</b>   |
| Optimization and restructuring expenses | 7.5                    | 2.7            | 10.2            |
| Transaction related costs               | 4.2                    | 3.1            | 7.3             |
| Non-cash charges                        | 2.0                    | -              | 2.0             |
| New contract setup                      | -                      | 0.9            | 0.9             |
| Oversight and management Fees           | 2.1                    | 0.4            | 2.5             |
| <b>Adjusted EBITDA</b>                  | <b>\$47.6</b>          | <b>\$16.7</b>  | <b>\$64.3</b>   |

(1) Net loss for the period is presented on the basis of the previous debt structure of the respective standalone companies that became Exela as a result of the Business Combination. As of July 12<sup>th</sup>, 2017 those debt structures were replaced with new debt consisting of \$350 million Term Loan and \$1.0 Billion Senior Secured Notes.

**Exela Technologies**  
**Schedule 4: Adjusted EBITDA Reconciliation - First Quarter 2018 vs. Second Quarter 2018**



| (\$ in millions)                        | <b>As Reported</b> |                 |
|---|--------------------|-----------------|
|   | <b>Q2 2018</b>     | <b>Q1 2018</b>  |
| <b>Net loss</b>                         | <b>(\$25.2)</b>    | <b>(\$24.0)</b> |
| Taxes                                   | 1.6                | 4.0             |
| Interest expense                        | 38.5               | 38.0            |
| Depreciation and amortization           | 36.4               | 38.0            |
| <b>EBITDA</b>                           | <b>\$51.3</b>      | <b>\$56.1</b>   |
| Optimization and restructuring expenses | 13.0               | 14.5            |
| Transaction related costs               | 0.8                | 1.1             |
| Non-cash charges                        | 5.6                | 1.3             |
| (Gain) / loss on derivative instruments | (0.7)              | (3.3)           |
| <b>Adjusted EBITDA</b>                  | <b>\$70.1</b>      | <b>\$69.6</b>   |

### **Exela Technologies**

#### **Schedule 5: SG&A (Including Related Party) - Pro Forma Second Quarter 2017, First Quarter 2018 and Second Quarter 2018**

| (\$ in millions)                             | <b>As Reported</b> |                | <b>Q2 2017</b>   |                    |                |
|--|--------------------|----------------|------------------|--------------------|----------------|
|  | <b>Q2 2018</b>     | <b>Q1 2018</b> | <b>Pro Forma</b> | <b>As Reported</b> | <b>Novitex</b> |
| Selling, general and administrative expenses | 46.7               | 45.6           | 49.4             | 35.0               | 14.4           |
| Related party expense                        | 1.4                | 1.1            | 2.4              | 2.4                | 0.0            |
| Total  | \$48.1             | \$46.7         | \$51.8           | \$37.4             | \$14.4         |

### **Exela Technologies**

#### **Schedule 6: Pro forma Revenue and Capital Expenditures Reconciliation TTM'18, FY2017 and FY2016**

(\$ in millions)

|                          | <b>As Reported<sup>(1)</sup></b> | <b>Novitex</b> | <b>Pro Forma</b> |
|--------------------------|----------------------------------|----------------|------------------|
| Revenue - FY 2018 TTM Q2 | \$1,528.2                        | \$19.8         | \$1,548.0        |
| Revenue - FY 2017        | \$1,152.3                        | \$304.0        | \$1,456.3        |



|                                |         |         |           |
|--------------------------------|---------|---------|-----------|
| Revenue - FY 2016              | \$789.9 | \$543.2 | \$1,333.1 |
| Capital expenditures - FY 2017 | \$33.3  | \$9.1   | \$42.4    |
| Capital expenditures - FY 2016 | \$35.6  | \$15.9  | \$51.5    |

(1) Financial results for FY 2016 do not include contribution for the first nine months from the acquisition of TransCentra which closed on September 25, 2016.

## Exela Technologies

### Schedule 7: Q2 2017 Revenue and Expense Reconciliation

| (\$ in millions)   | Q2 2017 <sup>(1)</sup> |                |                 |
|--|------------------------|----------------|-----------------|
|  | As Reported            | Novitex        | Pro Forma       |
| <b>Revenue</b>   | <b>\$209.4</b>         | <b>\$140.6</b> | <b>\$350.0</b>  |
| Cost of revenue (exclusive of depreciation and amortization)           | 140.4                  | 116.6          | 257.0           |
| Selling, general and administrative expenses (Including related party) | 37.5                   | 14.4           | 51.8            |
| Depreciation and amortization  | 21.4                   | 9.7            | 31.1            |
| <b>Operating income (loss)</b>   | <b>10.1</b>            | <b>(0.1)</b>   | <b>10.0</b>     |
| Interest expense, net  | 27.9                   | 12.2           | 40.0            |
| Sundry expense (income) & other income, net                            | (0.3)                  | -              | (.3)            |
| <b>Net loss before income taxes</b>                                    | <b>(17.4)</b>          | <b>(12.3)</b>  | <b>(29.7)</b>   |
| Income tax (benefit) expense   | 2.1                    | (3.9)          | (1.9)           |
| <b>Net loss</b>  | <b>(\$19.5)</b>        | <b>(\$8.4)</b> | <b>(\$27.9)</b> |

(1) Net loss for the period is presented on the basis of the previous debt structure of the respective standalone companies that became Exela as a result of the Business Combination. As of July 12th, 2017 those debt structures were replaced with new debt consisting of \$350 million Term Loan and \$1.0 Billion Senior Secured Notes.





---

Contact: Jim Mathias

E: [ir@exelatech.com](mailto:ir@exelatech.com)

W: <https://investors.exelatech.com>

T: +1 972-821-5808